Bachem’s Strong Run Masks Analyst Caution as Dividend Hike Offers Counterpoint

The Swiss peptide specialist Bachem has delivered one of the sector’s most eye-catching performances this year, with shares gaining nearly 30% since January. Yet beneath the surface lurks a curious disconnect: one key analyst house has lifted its price target by 5.57% to 77.90 francs, but kept its recommendation stuck at “Reduce.” The message is clear – the stock’s rally has already priced in much of the good news, leaving limited room for further upside.

AlphaValue/Baader Europe’s updated target reflects the surging demand for peptide-based drugs, especially in the diabetes and obesity space where Bachem’s manufacturing capacity and process know-how put it directly in the path of structural industry growth. The firm’s 2025 results underpin that optimism: revenue climbed nearly 15% to 695.1 million francs, while net profit reached 148.8 million francs. Management is aiming even higher, with a goal of breaching the 1-billion-franc revenue mark by the end of 2026.

A countervailing force comes from the dividend outlook. Market watchers expect the annual payout to rise to 1.00 franc per share for the coming fiscal year, up from 90 rappen a year earlier. That projection is backed by earnings estimates of 2.41 francs per share for 2026, a trajectory that reinforces confidence in the business model even as the current valuation keeps some investors wary.

Should investors sell immediately? Or is it worth buying Bachem?

Adding to the operational narrative, a key leadership change is underway. Torsten Wöhr, who served as Chief Commercial Officer and drove the build-out of the oligonucleotide business, is leaving for an external opportunity. Until a successor is named, Chief Executive Anne-Kathrin Stoller will take on the sales role directly. The transition arrives at a sensitive moment, when order intake, capacity planning and client relationships are tightly interwoven.

On the technical side, the stock’s Relative Strength Index (RSI) of 25.4 on a 14-day basis signals a short-term oversold condition, despite the year-to-date advance of 29.12%. At Wednesday midday the shares traded at 77.12 pounds sterling, a fractional dip from the prior session. This technical reading suggests that while the broader uptrend remains intact, the market has absorbed some aggressive selling in recent sessions.

Bachem’s relative steadiness stands out in a turbulent chemicals and pharma landscape. Competitor Brenntag suffered from logistics disruptions in the Middle East, while Merck raised its guidance after a strong start to the year. At home, Takeda’s drugmaker operations are slashing jobs at Swiss sites, yet Bachem continues to push expansion plans. That defensive niche positioning has helped cushion the stock from broader sector volatility.

All eyes now turn to July, when the half-year report is due. Margins, capacity expansion and order backlog will be put under the microscope. For now, the bull case rests on booming peptide demand and a rising dividend, while the bear case points to a valuation that leaves little margin for error. The interim numbers will likely determine which side gains the upper hand.

Ad

Bachem Stock: New Analysis - 14 May

Fresh Bachem information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bachem analysis...

en | CH0012530207 | BACHEM’S | boerse | 69329020 |